Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 3.23 Mil Enterprise Value: -7.02 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 57/100

Q3 2020 Matinas BioPharma Holdings Inc Earnings Call Transcript

Nov 06, 2020 / 01:30PM GMT
Release Date Price: €35.25 (-0.70%)
Operator

Greetings. Welcome to Matinas BioPharma Third Quarter 2020 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to Peter Vozzo, Investor Relations Representative for Matinas BioPharma. You may begin.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Latonya. Good morning, everyone, and thank you for joining the Matinas BioPharma third quarter 2020 results conference call. Earlier this morning, we issued a press release with our third quarter 2020 financial results along with business updates. The release is available on the Matinas BioPharma website under the Investors section.

Speaking on today's call would be Jerry Jabbour, Chief Executive Officer, who would discuss the company's corporate progress and key milestones; and Keith Kucinski, Chief Financial Officer, who will then review third quarter financial results. We also have Dr. Terry Matkovits, Chief Development Officer; and Dr. Terry Ferguson, Chief Medical Officer, available to answer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot